Ulinastatin-Fc (Samsung Bioepis/Takeda)
- Generic Name
- Ulinastatin-Fc (Samsung Bioepis/Takeda)
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Takeda
- Registration Number
- NCT04464460
A Phase I Study of SB26 in Healthy Volunteers
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT03630627
- Locations
- 🇺🇸
PAREXEL International, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath